Tag Archives: T-cell

November, 2017

October, 2017

  • 4 October

    Amgen and CytomX Enter Immuno-Oncology Collaboration

    THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and CytomX Therapeutics, Inc., (NASDAQ: CTMX) today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor …

January, 2017

  • 4 January

    Jounce Therapeutics Files for $75M IPO

    CAMBRIDGE, Mass., January 3, 2017 –Jounce Therapeutics, a clinical-stage immuno-oncology company, has filed an initial public offering  through which it hopes to raise $75 million in 2017. The Cambridge, MA-based company was founded in 2012 and employs a two-pronged approach to therapy development: using a translational science platform that targets …

  • 4 January

    Lycera’s RORgamma Agonist to Begin Phase 1 Trials

    NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. “We …

June, 2015